![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EMA Considers Using Big Data and Real-World Evidence in Approval Decisions
EMA Considers Using Big Data and Real-World Evidence in Approval Decisions
![EMA_Logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/EMA_Logo.gif?t=1579219264&width=430)
February 28, 2017
The EMA identified ways to address the drawbacks of using electronic healthcare records and real-world evidence to support drug development and regulatory decision-making.
Cloud-based systems and machine-learning algorithms, for example, could give drugmakers and the EMA the capacity to store, access and analyze the massive datasets from electronic healthcare records or other real-world sources.
Missing elements and other noise in the data can be overcome through analysis, corroboration, randomized trials and selectivity, according to an EMA report, which follows a big data workshop held late last year.
Upcoming Events
-
21Oct